A pharmacokinetic interaction and safety and efficacy phase II, open label study with a safety lead-in evaluating docetaxel plus tesmilifene (YMB1002) in patients with metastatic breast cancer suitable for treatment with docetaxel
Phase of Trial: Phase II
Latest Information Update: 08 Jan 2009
At a glance
- Drugs Tesmilifene (Primary) ; Docetaxel
- Indications Advanced breast cancer
- Focus Pharmacokinetics
- Sponsors YM BioSciences
- 08 Jan 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 09 Nov 2006 New trial record.